Epilepsy Market

Epilepsy Market Size (2023 to 2028)

The global epilepsy market size is forecasted to grow at a CAGR of 9.12% during the forecast period and be worth USD 2.77 billion by 2028 from USD 1.79 billion in 2023.

MARKET DRIVERS:

The growing geriatric population diagnosed with epilepsy worldwide is primarily driving the epilepsy market growth.

People with old age are more prone to epilepsy risk than young people, and thus most cases are of older people. In 40% of cases, the cause of epilepsy is a brain injury. Advancements have positively influenced the global epilepsy market in epilepsy therapeutics as their efficiency increases.

The rising government initiatives have resulted in more awareness among people and thus driven the market's growth. The increased research and development by entering private players in this market have developed the products and market dynamics by identifying the demand and supply chain. Although the market is extremely crowded with branded and generic drugs, pharmaceutical companies have shifted their focus to developing safe adjunctive therapies for refractory patients.

MARKET RESTRAINTS:

The significant restraints for the market are the lack of healthcare facilities and the low quality of healthcare services in many countries worldwide. Epilepsy is a disease related to the brain that requires complex procedures that can be made easy with better equipment and the lack of this equipment results in low success in brain surgeries. The lack of skilled healthcare professionals is also a major factor restraining the growth factor.

Impact of COVID-19 on the global epilepsy market: 

COVID-19 has negatively impacted the market. The prevalence of COVID-19 led to lockdowns in most areas around the world. It led to disruption in the supply chain of medical equipment and therapeutics required in treating epilepsy and thus negatively impacting the growth of the market. The emphasis by governments to improve their healthcare system due to the effects of a pandemic can have some positive impact on the market.

REPORT COVERAGE:

This research report on the global epilepsy market has been segmented & sub-segmented based on condition, diagnosis, treatment, end-user, and region.

Epilepsy Market - By Condition:

• Epilepsy drug-resistant / intractable epilepsy
• Others

The other sub-segment had the largest market share in 2022, with around 70% market share, and is expected to grow at a reasonable rate during the forecast period. The development of the healthcare system and the development of the therapeutics side of treatment is the main reason for the high growth of this segment. Increasing awareness will further drive the growth of the market.

The Epilepsy drug-resistant sub-segment had the second-largest market share in 2022, with an expected growth rate to be relatively high during the forecast period. The emergence of rational polytherapy for treating disorders with almost no side effects will drive the growth of this sub-segment. The increase in the number of cases due to the rise in the geriatric population worldwide is a significant reason for this sub-segment to grow.

Epilepsy Market - By Diagnosis and Treatment:

• Diagnosis
• Treatment

Based on the diagnosis and treatment, the treatment sub-segment had the largest market share with a 66% share in the market with an expected positive rate during the forecast period. The growth rate projected for the forecast period is 6.81%. The treatment segment has been sub-segmented into anti-epileptic drugs, neurostimulation devices, brain surgery, ketogenic diet, etc. The main reason for the highest market share is the availability of affordable drugs for treating partial epileptic seizures. The approval of effective drugs by regulatory bodies is also an essential factor for market growth.

The diagnosis segment had the second largest market share in 2022 and is expected to grow fastest with a CAGR of 8.2% during the forecast period. The diagnosis segment has been further sub-segmented into imaging devices, blood tests, and others. The utilization of imaging tests and blood tests for the early diagnosis of the disease has driven the growth of this market. The imaging tests like CT scans can reveal the abnormalities associated with the brain and thus can be proved very helpful.

Epilepsy Market - By End-User:

• Hospitals
• Clinics
• Ambulatory Surgical Centres
• Diagnostic Centres
• Others

Hospitals and Clinics had the largest market share of 35% in 2022 and are expected to grow reasonably during the forecast period. The development of healthcare facilities and the rising quality of healthcare infrastructure will further increase the growth rate. The increase in cases of epilepsy is also a significant contributing factor.

Clinics are expected to grow at the highest rate during the forecast period, with a 9.82% CAGR. Adoption of the latest equipment by doctors to provide excellent patient care can spur the growth of the segment. The increase in cases of epilepsy will help the market to grow at a reasonable rate.

Epilepsy Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American region had the highest share of around 41% in 2022 in the global epilepsy market and is expected to grow reasonably during the forecast period. The increase in the geriatric population and improvement in a healthcare facility is the primary market growth driving factors.

Europe region had the second-largest market share with a healthy growth rate projection in the future. The advancement in technology and rising initiatives from the government Is the main reason for market growth.

Asia Pacific region is expected to grow with the highest growth rate during the forecast period. The increase in epilepsy cases due to the rise in population in countries like India and China is the main reason for the high market growth rate. Growing awareness and improved medical structure will also help the market to grow.

KEY MARKET PARTICIPANTS:

Companies that are playing a dominating role in the global epilepsy market analyzed in this report are LivaNova, NeuroPace, GlaxoSmithKline PLC, Johnson and Johnson Services, Medtronic PLC, Eisai, GW Pharmaceuticals, UCB SA, Pfizer, Novartis AG, Takeda, Abbott Laboratories, Bausch Health, Sanofi and Sunovion Pharmaceuticals.